SOURCE: BioPharm Insight

BioPharm Insight

January 25, 2011 09:20 ET

BioPharm Insight Provides Forward-Looking Intelligence to the Biotechnology & Pharmaceutical Industry

LONDON and NORWOOD, MA--(Marketwire - January 25, 2011) -  BioPharm Insight, the premier data and intelligence provider for Biotechs, Pharmas, CROs, Service Providers and financial professionals in the Healthcare and Medtech markets, is pleased to announce the launch of its new, upgraded product platform. The new platform features proprietary, forward-looking intelligence, new search functionality, a worldwide reference list of approved drugs and drug sales projections by indication.

BioPharm Insight's comprehensive platform tracks the entire drug development pipeline from discovery and tech transfer platforms to approved drug licensing and generic formulations. Subscribers will gain access to:

  • Detailed company profiles for over 4,200 Biotech and Pharmaceutical companies
  • Contact information for 250,000+ industry contacts
  • Exclusive, real-time intelligence from our global editorial team
  • 36,000+ investigational drug profiles including development history, clinical trials, mechanisms, patent expiration dates, molecular structures, sales projections, and licensing deals
  • 50,000+ approved drug profiles, foreign trade names, and marketing authorization by country

BioPharm's team of specialized journalists provides global coverage of major medical conferences and material situations that highlight pivotal data presentations and analysis in advance of industry meetings and market-moving events. Areas of focus for the team include drug development, medical devices, diagnostics, M&A, licensing and financing, regulatory issues, litigation, and healthcare services.

"Bringing exclusive, real-time editorial content under the BioPharm brand allows us to provide a first-rate product for our clients. Integrating the content of our global network of journalists with BioPharm's in-depth data means we can service the needs of our clients in biotech, pharma, CROs, service providers and financial services with one product," says Ruth McHenry, Managing Director, Infinata, Inc. "The BioPharm brand now represents a robust service of forward-looking intelligence, drug pipelines, licensing agreements, clinical trial results, management contacts, forecasting, and clinical investigators. This change makes BioPharm Insight a one stop solution for our clients, and the best product of its kind."

Incorporated in 1999, BioPharm Insight gives subscribers access to comprehensive drug, company, and management contact profiles, customizable searches, reports, and email alerts and first-class client support teams. The intelligence component of the service, previously known as Pharmawire, complements the comprehensive database of drugs and devices in development by offering industry-wide intelligence on upcoming material events in the sector.

About Infinata & BioPharm Insight
Infinata is a wholly-owned subsidiary of the Financial Times Group, publisher of the Financial Times newspaper and The life sciences suite of products: BioPharm Insight, BioPharm Devices and BioPharm Clinical provide a fully integrated information suite covering the data, search, networking, and intelligence needs of the Pharmaceutical, Biotech, CRO, Device and Medtech community. For product and sales information, visit:

Contact Information